Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection Using cGMP

Shigella Clinical Trial

Official title:
Safety, Clinical Tolerance, and Immunogenicity of CVD 1208S, a Delta guaBA, Delta Sen, Delta Set, Live, Oral Shigella Flexneri 2a Vaccine Manufactured Using cGMP

Status Completed

Clinical Trial Summary

The purpose of this study is to determine whether CVD 1208S (a live, attenuated, oral vaccine) is safe and effective in the prevention of Shigella infection.

Clinical Trial Description

There are two purposes for conducting this Vaccine Study to evaluate an experimental vaccine called CVD 1208S (Center for Vaccine Development 1208S): 1) to learn whether CVD 1208S causes side effects, and 2) to learn whether the CVD 1208S gives people immunity to Shigella. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01531530
Study type	Interventional
Source	University of Maryland, Baltimore
Contact
Status	Completed
Phase	Phase 1
Start date	July 2011
Completion date	September 2012

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01080716` - Safety and Efficacy Study of WRSS1, a Shigella Sonnei Vaccine Candidate	Phase 1/Phase 2
Active, not recruiting	`NCT04078022` - Shigella CVD 30000: Study of Responses to Vaccination With Shigella Vaccine	Phase 2
Terminated	`NCT00866242` - Safety and Efficacy Challenge Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella: Phase IIb	Phase 2
Terminated	`NCT00866476` - Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection: Phase IIa	Phase 2
Enrolling by invitation	`NCT03778125` - Multidrug Resistant Shigella Infection in Bangladesh
Recruiting	`NCT06047821` - Enterics for Global Health (EFGH)